- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01555944
Prospective Observational Study in Patients With Metastatic Breast Cancer Treated With Anthracyclines
Screening and Management of Cardiovascular Risk in Belgian Women Aged > or = 65 Years With Metastatic Breast Cancer Before and After Anthracycline Treatment
This is an open, multicentre, prospective observational (non-interventional) study, performed in Belgium.
Principal objectives:
- To evaluate the prevalence of cardiovascular risk factors and cardiac function (as routinely evaluated) before treatment with anthracyclines of patients with metastatic breast cancer (MBC) aged > or = 65 years
- To observe the management of cardiovascular risk during and after anthracycline treatment
- To compare liposomal versus non-liposomal anthracycline therapy (ratio 1:1) on cardiac function, outcome and quality of life (EORTC QLQ-C30)
Secondary objectives:
- To evaluate the efficacy of anthracyclines on progression free survival and tumor response as routinely measured (e.g. recist criteria, tumor markers and other exams)
- To evaluate cardiovascular event type: ECG changes, arrhythmia, decrease of ejection fraction, heart failure and rate according to allocated treatment.
- To find out how quality of life, e.g. such as described according to EORTC QLQ-C30 criteria or Karnofsky index is achieved in the various patient subgroups
- To correlate the therapeutic choice and posology of anthracyclines for MBC with Cardiovascular risk at baseline
- To calculate the cardiovascular risk according to SCORE
Aperçu de l'étude
Statut
Les conditions
Description détaillée
The physician will be requested:
- To include 15 consecutive patients aged > or = 65 years who will be treated with anthracyclines in first and second line MBC. The physician will be encouraged to enrol 2 arms of 8 patients (one treated with liposomal and one with non-liposomal anthracyclines) for observation and comparison. Each arm will be closed as soon as 150 patients are included at a national level.
- To report their cardiovascular risk factors
- To provide the results of routinely performed cardiac evaluation before treatment
- To monitor routinely cardiovascular parameters during treatment and report them afterwards
- To monitor efficacy and tolerance of treatments, as normal practice prescribes, reported and related to the variables described in objectives
- To ensure that quality of life will be assessed with the EORTC QLQ-C30 questionnaire
- To monitor and report progression free survival and cardiac events
- To record and transmit spontaneously reported adverse events. These will be handled according to legal requirements
Follow-up will cover a period of 15 months following inclusion.
The study will have 3 visits and 2 contacts:
- One visit at entry
- One visit after 3 cycles of anthracycline containing therapy
- One visit at the end of treatment
- Contact at 9 months after inclusion
- Contact at 15 months after inclusion
It is planned to include data from 15 consecutive female patients per specialized center in Belgium.
The total number of patients aimed is 300.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
-
Antwerp, Belgique, 2020
- ZNA Middelheim
-
Arlon, Belgique, 6700
- Cliniques du Sud Lux - St Joseph
-
Bonheiden, Belgique, 2820
- Imelda
-
Bouge, Belgique, 5004
- Clinique Saint-Luc
-
Brasschaat, Belgique, 2930
- AZ Klina
-
Brugge, Belgique, 8000
- AZ St Jan
-
Brussel, Belgique, 1090
- UZ Brussel
-
Brussels, Belgique, 1020
- CHU Brugmann
-
Brussels, Belgique, 1070
- Erasme
-
Brussels, Belgique, 1180
- CHIREC - Centre Hospitalier Interrégional Edith Cavell
-
Chimay, Belgique, 6460
- CSF
-
Duffel, Belgique, 2570
- AZ St-Maarten
-
Edegem, Belgique, 2650
- UZA
-
Geel, Belgique, 2440
- AZ St-Dimpna
-
Ghent, Belgique, 9000
- AZ St-Lucas
-
Merksem, Belgique, 2170
- ZNA Jan Palfijn
-
Namur, Belgique, 5000
- CMSE
-
Namur, Belgique, 5000
- CHR
-
Oostende, Belgique, 8400
- AZ Damiaan
-
Ottignies, Belgique, 1340
- Clinique St Pierre
-
St-Niklaas, Belgique, 9100
- AZ Nikolaas
-
Tournai, Belgique, 7500
- Centre Hospitalier de Wallonie picarde - site IMC
-
Verviers, Belgique, 4800
- CHPLT
-
Yvoir, Belgique, 5530
- CHU Mont-Godinne
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Belgian women aged > or = 65 years with metastatic breast cancer before and after anthracycline treatment.
Patients will be included in 24 centers specialized in the treatment of breast cancer, in Belgium.
La description
Inclusion Criteria:
- women aged 65 years old or more
- with confirmed metastatic breast cancer (MBC)
- who will be treated with anthracyclines in first or second line
- who have a Karnofsky score at baseline of 50
- who agree and are able to fill in the EORTC QLQ-C30 questionnaire
- who gave their informed consent
Exclusion Criteria:
- women having contra-Indications for anthracyclines
- women aged < 65 years old
- with no metastatic breast cancer
- who will not be eligible for an anthracycline treatment in first or second line MBC
- who have a Karnofsky less than 50
- who disagree or are unable to fill in the EORTC QLQ-C30 questionnaire
- women refusing or not having signed their informed consent
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
cardiovascular risk factors
Délai: 15 months
|
15 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Christel Fontaine, MD, Universitair Ziekenhuis Brussel
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- MyCard
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Cancer du sein métastatique
-
AstraZenecaRecrutementAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian CancerEspagne, États-Unis, Belgique, Royaume-Uni, France, Hongrie, Canada, Corée, République de, Australie